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ABSTRACT  
Background: Autism spectrum disorders (ASDs) are characterized by persistent deficits in social communica-
tion and interaction and restricted, repetitive patterns of behavior, interests or activities. In most cases, the 
cause of ASD is likely to be a combination of genetic predisposition and environmental exposures occurring 
in fetal life or early infancy. Consequently, a prospective pregnancy cohort like MoBa represents an ideal 
platform for studies of ASDs in children. 
Methods: The Autism Birth Cohort (ABC) Study has identified potential ASD cases in MoBa through ques-
tionnaire-based screening, parental and professional referrals, and linkages to the Norwegian Patient Register. 
ASD diagnoses have been ascertained through in-person clinical assessments and medical record reviews. 
Current results: By the end of 2012, the ABC Study had identified 518 ASD cases in MoBa. The ASD 
prevalence in school-age children is 0.7-0.8%, which is in line with nationwide estimates for Norway. The 
most important source of ASD case identification was registry linkages, while only a minority was detected 
through early screening. Published findings show that screening at 18 months misses the majority of ASD 
cases. Analyses of risk factors for ASDs have shown that maternal use of folic acid supplements in early 
pregnancy may lower the child’s risk of developing ASDs and that paternal obesity appears to increase the 
child’s risk of ASDs. 
Future plans: ASD case identification will continue through annual registry linkages and subsequent reviews 
of medical records. Analyses of plasma samples and RNA samples will be conducted to investigate prenatal 
and perinatal microbial exposures, innate immune and inflammatory responses, biomarkers of autism risk, and 
exposures to xenobiotics. Analyses of deciduous teeth will also investigate the effect of medications and 
environmental toxins. Exome sequencing of DNA from ASD cases and their parents is ongoing, and will 
elucidate the role of de novo DNA mutations in the pathogenesis of ASDs. Future epidemiological analyses 
will explore the results of the 36-month screening for ASDs, the diagnostic stability and developmental 
trajectories in ASD children, and psychiatric and medical comorbidities in ASDs. 
 
This is an open access article distributed under the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original work is properly cited. 
 
 
PURPOSE OF THE ARTICLE 
 
The purpose of this article is to describe the Autism 
Birth Cohort (ABC) Study, the sub-study of autism 
spectrum disorders (ASDs) in MoBa. We start by 
providing background information about ASDs, as this 
is necessary to explain why a prospective pregnancy 
cohort is an excellent platform for studies of ASDs in 
children. We then describe how the ABC Study has 
been managed and conducted, what the current results 
are, and what plans we have for the future of the study. 
AUTISM SPECTRUM DISORDERS (ASDS): 
BACKGROUND 
 
Clinical features  
Autism spectrum disorders (ASDs) constitute a hetero-
geneous group of neurodevelopmental disorders defined 
by (1) persistent deficits in social communication and 
social interaction across multiple contexts and (2) re-
stricted, repetitive patterns of behavior, interests or 
activities (1). Symptoms of autism may vary in seve-
rity and time of onset, and children with ASDs display 
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a wide range of cognitive skills, from high intelligence 
to profound mental retardation (2). Around 50% have 
intellectual disability (IQ below 70), although the 
exact proportion is uncertain (2). ASDs are diagnosed 
according to the Diagnostic and Statistical Manual of 
Mental Disorders (Fifth Edition) (DSM-5) (1) or the 
International Classification of Diseases (10th Revi-
sion) (ICD-10) (3). The DSM classification is used in 
clinical practice in North America and is the basis for 
research-standard diagnoses of ASDs. The DSM-5 was 
introduced in 2013 to replace the DSM-IV(4), which 
was used from 1994-2013. The ICD-10 is the standard 
classification system used in clinical practice in Europe 
and employs the term “pervasive developmental disor-
ders” (PDDs) for ASDs. The research-standard instru-
ments for diagnosis of ASDs are the Autism Diagnostic 
Interview – Revised (ADI-R) (5) and the Autism Diag-
nostic Observation Schedule, Second Edition (ADOS-
2) (6). The ADI-R is a parent interview, whereas the 
ADOS is a semi-structured, standardized assessment 
of the child’s social interaction, communication, and 
imaginative play. Both instruments are now widely 
used in both research and clinical practice. 
 The concept of autism as a developmental disorder 
was introduced by Leo Kanner in his article about 
children with “inborn autistic disturbances of affective 
contact” in 1943 (7) and by Hans Asperger in his case 
series with descriptions of “autistic psychopathy” in 
children in 1944 (8). Throughout the 1950s and 1960s, 
the condition was usually referred to as “childhood 
schizophrenia”, and it was not established as a separate 
diagnostic entity until the advent of the DSM-III 
classification in 1980 (9). The DSM-III used the term 
“infantile autism”, but in 1994, this was replaced by 
“autistic disorder” in the DSM-IV (4). Autistic 
disorder was defined as a disorder involving three do-
mains: (1) impairment in social interaction, (2) impair-
ment in communication, and (3) restricted, repetitive 
and stereotyped patterns of behavior, interests and 
activities (4). The DSM-IV also introduced two other 
subtype diagnoses of autism: Asperger’s disorder and 
“pervasive developmental disorder not otherwise spe-
cified” (PDD-NOS). Asperger’s disorder differed from 
autistic disorder in that there was no significant early 
delay in language acquisition (4). PDD-NOS was used 
for children who displayed impairments in reciprocal 
social interaction and symptoms within one of the 
other domains, but who did not meet the criteria for 
autistic disorder or Asperger’s disorder (4). PDD-NOS 
was regarded to be a sub-threshold diagnosis in 
relation to the two others, in the sense that individuals 
with this diagnosis were less severely affected by the 
core symptoms of autism (4). The ICD-10 uses the 
terms “childhood autism” for autistic disorder, “Asper-
ger syndrome” for Asperger’s disorder, and “atypical 
autism”, “other PDD” or “unspecified PDD” for PDD-
NOS. 
 There was substantial clinical overlap between the 
ASD subtype diagnoses of the DSM-IV. There was 
also wide variability in clinical presentation within the 
subtypes, and they were found to have low reliability 
across assessment sites (10). The subtype diagnoses 
did not convey any information about other clinically 
relevant characteristics such as cognitive function and 
language level. All of these limitations led to the 
removal of the subtype diagnoses from the DSM-5 in 
2013 (1). The ASD diagnosis of the DSM-5 is meant 
to be more informative by requiring that the diagnosis 
be accompanied by specifications of: (1) symptom 
severity on a scale from 1 to 3, (2) whether or not 
intellectual disability is present, (3) whether or not 
language impairment is present, (4) known medical or 
genetic conditions or environmental factors likely to 
have been involved in the pathogenesis, (5) other 
coexisting neurodevelopmental, mental or behavioral 
disorders, and (6) whether or not catatonia is occurring 
(1). A new version of the ICD is scheduled for 2015, 
and this will most likely also remove the subtype 
diagnoses of ASDs (11). 
 Several screening instruments for ASDs have been 
developed, and early screening for ASDs is widely 
recommended. Guidelines from the American Aca-
demy of Pediatrics state that all children should be 
screened for ASDs at age 18 months (12). However, 
none of the currently available screening instruments 
have been evaluated in large population-based samples 
of young children, and the effectiveness of early scree-
ning is debated (13). 
 
Prevalence  
The prevalence of diagnosed ASDs has increased 
rapidly in most developed countries over the past 20 
years, and is still increasing. The main cause appears 
to be changing diagnostic practices, with more children 
with lighter symptoms now receiving ASD diagnoses 
(14). However, a genuine increase in the occurrence of 
ASDs cannot be ruled out (15). A 2009 review of 
available epidemiological studies showed that most 
studies estimated the prevalence of ASDs to be 
between 0.6% and 0.7% in pre-school and school-age 
children in Europe and North America (16). Recent 
studies from the United States (17) and the United 
Kingdom (15) have demonstrated higher prevalence 
rates, of 1.1% and 1.2%, respectively. The ASD pre-
valence is much higher in boys than in girls. Estimates 
of male-to-female ratios range from 2:1 to 6.5:1 (2). 
The male-to-female ratio is particularly high for so-
called high-functioning autistic disorder (autistic dis-
order with normal-range IQ [IQ≥70]) and Asperger’s 
disorder (2). 
 
Prognosis and developmental outcomes  
The diagnostic stability of ASDs is high for children 
diagnosed at two years of age, indicating that ASDs 
are generally lifelong conditions for these children 
(18). However, children diagnosed at such an early age 
are likely to be the ones who are more severely affec-
ted. The diagnostic stability of ASDs detected at later 
THE AUTISM BIRTH COHORT (ABC) IN MOBA  41 
ages, with less severe symptoms, has not been inves-
tigated in large population-based study samples. There 
is no “cure” for ASDs, but there is some evidence that 
early diagnosis and intervention improve the develop-
mental outcomes (19). Positive prognostic factors are 
the presence of joint attention skills and functional 
play skills, the establishment of functional language 
before the age of five years, and IQ within the normal 
range (≥70) (1,2). Negative prognostic factors are high 
levels of symptom severity, intellectual disability, 
absence of functional language at age five years, 
coexisting epilepsy, and coexisting medical and 
psychiatric disorders (1,2). 
 
Risk factors  
Genetic factors play a major role in the pathogenesis 
of ASDs, and the disorder is highly heritable. Most 
twin studies have estimated the heritability of autistic 
disorder and ASDs to be between 70% and 90% (20), 
but two recent studies found considerably lower herita-
bility for ASDs in general, at 38% (21) and 50% (22), 
respectively. More research is needed to determine the 
heritability of ASDs more precisely, but the recent 
findings indicate that environmental exposures may 
have a more prominent role than previously assumed. 
 Conventional genetic diagnostic tools may demon-
strate an autism-related genetic variant in up to 20-25% 
of individuals with ASDs (23), but this proportion is 
likely to increase as the diagnostic repertoire expands. 
The contributing genetic factors appear to be hetero-
geneous, and a wide variety of genetic markers have 
been implicated (24). No single genetic variant has 
been shown to account for more than 1-2% of the total 
number of cases (24). This is part of the explanation of 
why genome-wide association studies have not been 
very successful at detecting genetic markers of ASDs; 
genome-wide association studies can only detect asso-
ciations for alleles occurring with a frequency of 1% 
or more in the population. The most promising app-
roach for identifying genetic markers of ASDs is to 
use the new methods for deep sequencing of DNA that 
are now becoming available. Studies using exome 
sequencing, a sequencing method covering the protein-
coding regions of DNA (1.5-2% of the entire genome) 
have detected a number of potentially causative de 
novo copy number variants with strong associations 
with ASDs (25-28). 
 Most research on environmental risk factors for 
ASDs points towards pregnancy or early infancy as the 
critical period. Epidemiological studies have identified 
a number of prenatal and perinatal exposures associa-
ted with an increased risk of ASDs in children. The 
risk factors with the strongest supporting evidence are 
(1) advancing paternal age, (2) maternal medication 
use during pregnancy, (3) maternal infection and 
immune responses during pregnancy, and (4) birth 
complications and adverse birth outcomes. 
 For advancing paternal age, it has been proposed 
that the association with ASDs is explained by an 
increase in de novo mutations in children of older 
fathers (29). For maternal medication use during preg-
nancy, large-scale studies have found an increase in 
risk associated with selective serotonin reuptake inhi-
bitors (30,31), other monoamine reuptake inhibitors 
(31), and valproate (32). 
 The potential ASD risk associated with maternal 
infection and immune responses during pregnancy 
came to light from the follow-up studies of children 
with congenital rubella syndrome, which showed that 
high proportions of these children developed autism 
(33). More recent epidemiological studies have found 
maternal fever and infection during pregnancy to be 
associated with increased risk of ASDs in children, but 
no specific pathogens have been implicated (34). 
Evidence from animal studies suggests that the 
deleterious effects of maternal immune responses are 
mediated by maternal IgG antibodies reacting with 
proteins in the fetal brain (34). 
 The studies of birth complications and adverse birth 
outcomes differ in terms of exactly which factors are 
predictive of increased ASD risk. It is also unclear 
whether these risk factors are potential causes of ASDs 
or whether the associations could be explained by 
reverse causation, i.e., that the children’s developmen-
tal disorders may in fact be the underlying causes – not 
the consequences – of birth complications and adverse 
birth outcomes. 
 Some proportion of ASD cases can probably be 
explained solely on a genetic basis, but the patterns in 
which ASDs occur in families suggest that the under-
lying genetic liabilities for ASDs are often predispo-
sitions rather than deterministic causes, and that the 
pathogenesis may involve interaction between genetic 
factors and environmental exposures. Furthermore, 
even in those cases where genetic variants are the only 
cause, the disease-specific gene variants may in turn 
be mutations caused by environmental exposures. 
Consequently, investigations of environmental expo-
sures are crucial to increase our understanding of why 
ASDs arise and what could potentially prevent them 
from occurring. 
 
THE AUTISM BIRTH COHORT (ABC) STUDY: 
METHODS AND DESIGN 
 
Scientific aims  
The following scientific aims were formulated for the 
ABC Study when the initial grant was obtained from 
the National Institute of Neurological Disorders and 
Stroke (NIH/NINDS) in 2003:  
1) Establish the Autism Birth Cohort (ABC) through 
ascertainment of potential ASD cases and selection 
of controls from the MoBa cohort. 
2) Identify environmental factors that may be directly 
or indirectly associated with ASDs including: pre-
natal or postnatal infection, mumps-measles-rubella 
vaccination, very low birth weight and prematurity, 
other obstetric risk factors in which infections are 
implicated, and dietary and/or environmental expo-
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sure to methylmercury during pregnancy and post-
natal life. 
3) Describe the natural history of clinical, anthropo-
metric, and neurobehavioral features of ASDs. 
 
Genetics were not included in the original scientific 
aims, because the first NINDS grant did not include 
funding for genetic studies. The intention was to 
obtain funding for genetic analyses through separate 
grants later on. An exome sequencing project based on 
the ABC Study has been funded by the Research 
Council of Norway and is now ongoing. 
 
 
 
Figure 1.  ABC Study: ASD Case Identification. MoBa = 
Norwegian Mother and Child Cohort Study. ABC = 
Autism Birth Cohort. ASD = Autism spectrum disorder. 
 
 
Identification of potential ASD cases  
An overview of the case-finding mechanisms of the 
ABC Study is provided in Figure 1. Cases of ASDs 
have been identified through (1) questionnaire scree-
ning of MoBa mothers at offspring ages three, five, 
and seven years, (2) professional and parental referrals 
of children suspected of having ASDs, and (3) link-
ages to the Norwegian Patient Register (NPR). The 
screening at three years was implemented for MoBa 
participants born in February 2002 and later. The 
MoBa 36-month questionnaire included the Social 
Communication Questionnaire (SCQ), a 40-item ques-
tionnaire that has previously been validated for ASD 
screening in clinic-based samples of school-aged 
children with ASDs (35). The ABC Study used the 33 
non-verbal items of the SCQ (the SCQ-33) and other 
selected questions from the 36-month questionnaire for 
ASD screening. The screening algorithm was designed 
to achieve a high sensitivity for ASDs, and also to 
identify children with disorders that are closely related 
to ASDs, such as language disorders. The screening in 
the 5- and 7-year questionnaires was based on direct 
questions about autistic disorder, Asperger syndrome, 
and/or autistic traits. The details of the screening pro-
cedures are described in Table 1. 
 Referrals from parents and health professionals 
were elicited through annual newsletters to MoBa 
participants and information on the website of the 
Norwegian Institute of Public Health (www.fhi.no). 
Referrals were accepted if the child was a MoBa parti-
cipant and there was reason to believe the child might 
have an ASD. 
 Linkages to the NPR have been conducted annually 
since 2009, and the ABC Study was the first study to 
utilize NPR data for research purposes. The NPR coll-
ects data on diagnoses from all hospitals and outpatient 
clinics in Norway, beginning in the year 2008, thereby 
capturing all children diagnosed with ASDs by 
Norwegian health services. The NPR contains ICD-10 
(3) codes, and potential ASD cases in the ABC Study 
are MoBa participants recorded with codes F84.0 
(childhood autism), F84.1 (atypical autism), F84.5 
(Asperger syndrome), F84.8 (other PDD), or F84.9 
(PDD, unspecified). 
 
ASD case ascertainment  
When a child with ASD or potential ASD was detected 
through any of the mechanisms described above, 
he/she was invited to participate in a clinical assess-
ment that included the ADI-R (5) and the ADOS (6). 
These instruments were not available in Norwegian 
prior to the inception of the ABC Study, so they were 
translated from the original English versions by autho-
rized translators. The primary purpose of the clinical 
assessment was to determine whether the child had 
ASD or not, and the secondary purpose was to collect 
information about phenotypic characteristics that may 
distinguish between subtypes of ASDs. The compo-
nents of the clinical assessment are described in Tables 
2-3. The assessments were conducted without know-
ledge of previous questionnaire responses. Diagnostic 
conclusions were best-estimate clinical diagnoses 
derived from test and interview results and from 
information collected from parents and teachers. The 
diagnoses were based on DSM-IV-TR (4) criteria, and 
the ASD case definition included codes 299.00 
(autistic disorder), 299.80 (Asperger’s disorder), and 
299.80 (PDD-NOS). 
 The characterization of ASD cases that have not 
been clinically assessed will occur through medical 
record reviews. The data collected through this review 
are described in Table 4. The review will be completed 
by evaluating whether the DSM-IV criteria for any of 
the subtypes of ASDs are met. The ABC Study will 
continue to use the DSM-IV criteria, but the data 
collected will enable a future change to the DSM-5 
criteria if needed. 
 
Selection of controls  
For the analyses based on questionnaire and registry 
data the entire MoBa cohort is used as the control 
sample. For the biological analyses, an ABC-specific 
control group has been established for which the 
MoBa biological materials from children and parents 
are reserved for use by the ABC Study. Controls were 
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Table 1.  ABC Study: ASD Screening Procedures. 
 
36-month screening criteria 
Criterion 1 SCQ-33 (35) score ≥12 
Criterion 2  Repetitive behavior sub-domain score on the SCQ-33 = 9 (full score) 
Criterion 3 Parent reports language delay AND child has been referred to a specialist 
Criterion 4 Parent reports autism/autistic traits AND/OR child has been referred to a specialist 
Criterion 5 Parent reports that the child shows very little interest in playing with other children 
Criterion 6 Parent reports that others (well-baby nurse, teacher, family member) has  
expressed worry about the child’s development   
36-month screening algorithms 
Born Feb 1, 2002 – Jun 30, 2002: Meeting criterion 4 or [criterion 3 and 5] 
Born July 1, 2002 – Jan 31, 2004: Meeting any one of criteria 1-5 
Born Feb 1, 2003 or later: Meeting criterion 4 or [any one of criteria 1-5 AND criterion 6] a   
5-year and 7-year screening  
Parent reports autistic disorder, Asperger’s disorder AND/OR autistic traits 
ABC = Autism Birth Cohort. ASD = Autism spectrum disorder. SCQ = Social Communication 
         Questionnaire (40 items) (35). 
SCQ-33 = the 33 non-verbal items of the SCQ.  
a Criterion 6 was added because the specificity of the initial algorithm (any one of criteria 1-5) was too low.  
 
 
Table 2.  ABC Study: Clinical Assessment Components. 
 
Dimension Standardized instrument Mode 
ASD symptoms Autism Diagnostic Interview – Revised (ADI-R) (5) Parent interview 
ASD symptoms Autism Diagnostic Observation Schedule (ADOS), First Edition (6) Child structured observation 
Cognitive function 
Children aged 3-5 years: 
Stanford-Binet Intelligence Scale, 5th Ed. (SB-5) (60) Child test 
Children aged ≥6 years: 
Wechsler Abbreviated Scale of Intelligence (WASI) (61)  Child test 
Children too low-functioning for SB-5/WASI:  
Mullen Scales of Early Learning (62) Child test 
Language function Vineland Adaptive Behavior Scales (VABS) (63), communication sub-domain Parent interview 
Motor function Mullen Scales of Early Learning (62), motor domain Child test 
Other assessment components 
Physician history-taking: Full medical and developmental history 
Physical examination: Neurological function, dysmorphic traits 
Photography: Frontal and side photos of head, photos of skin lesions (if any) 
Anthropometric measurements: Length, weight, head circumference 
ABC = Autism Birth Cohort. ASD = Autism spectrum disorder. 
 
 
selected before ASD cases were identified, so that 
everyone was eligible to become a control and the 
control group is representative of the whole cohort. 
The sampling was done every other week on those 
who had attained 37.5 months of age in the two pre-
ceding weeks, and the sampling algorithm was desig-
ned to capture 1.63% of MoBa participants on average. 
About half of these selected controls were invited to 
participate in the clinical assessment (two or three per 
calendar week). 
 
Ethical, legal, and social aspects  
The ABC Study has a permit from the Norwegian Data 
Inspectorate and approvals from the Regional Com-
mittee for Medical and Health Research Ethics for 
Southeastern Norway and the Institutional Review 
Board at Columbia University. 
 MoBa participants who were invited to participate 
in the clinical assessments of the ABC Study received 
a separate invitation brochure that contained informa-
tion about the scientific rationale for the study, the 
collaborators involved, and the content of the clinical 
assessment. They were informed that participation was 
voluntary and that their choice would not have any 
influence on their continuing participation in MoBa. 
Participation in the assessment required written consent 
by the parents. 
 For ASD cases and selected controls who did not 
participate in the clinical assessment, the use of data 
and biological materials rests upon the broad consent 
signed upon recruitment to MoBa. This broad consent 
was based on an information brochure describing the 
MoBa data collection and what the consent entailed. 
The initial information brochure has been followed up 
by annual newsletters to all MoBa participants and by 
specific newsletters to participants in various MoBa 
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Table 3.  ABC Study: Pre-Assessment Forms (Parents and Teachers). 
 
Dimension Standardized instrument 
Psychiatric difficulties a 
Children aged 3-years:  
Early Childhood Inventory – version 4 (ECI-4) (64,65) 
Children aged ≥6 years: 
Child Symptom Inventory – version 4 (CSI-4) (66) 
Language function Child Development Inventory (CDI) (67) 
Executive function Behavior Rating Inventory of Executive Function (BRIEF) (68,69) Preschool version for ages 3-years, regular version for ages ≥6 years 
Temperament Parents only: Child Behavior Questionnaire (CBQ) (70, 71) 
Play and social interaction Teachers only: Preschool Play Behavior Scale (PPBS) (72) 
ABC = Autism Birth Cohort 
a During 2005-2008, psychiatric difficulties were assessed through the Preschool Age Psychiatric Assessment (PAPA) (73). 
 
 
Table 4.  ABC Study: Medical Record Review. 
 
Dimension Data collected 
Referral and assessment history Time of referral, examinations performed, time of ASD diagnosis 
ASD symptoms 
Autism Diagnostic Interview – Revised (ADI-R) (5):  
Full scores if available, otherwise algorithm scores 
Autism Diagnostic Observation Schedule (ADOS) (6):  
Full scores if available, otherwise algorithm scores 
Cognitive function Any test result available 
Language function Any test result/parent interview available 
Executive function Any test result/parent interview available 
Adaptive function Any test result/parent interview available 
Other psychiatric and neuro- 
developmental disorders Other ICD-10 diagnoses recorded 
DSM-IV criteria Evaluation of whether criteria are met for any of  the subtype diagnoses of ASDs 
ABC = Autism Birth Cohort. ASD = Autism spectrum disorder.  
 
 
sub-studies. Information about the ABC Study has 
been included in all annual MoBa newsletters since 
2005. The 2013 edition of the newsletter included a 
thorough description of the genetic analyses planned in 
MoBa sub-studies, including the ABC Study. In 2013, 
the ABC Study also published a separate newsletter 
with an overview of the study results and the future 
plans for the study. This ABC-specific newsletter went 
out to everyone who had participated in the clinical 
assessments, to ASD cases identified from the NPR, 
and to all selected controls who had not been clinically 
assessed. 
 The ABC Study was the first Norwegian study to 
use deep sequencing of DNA for research purposes. 
Exome sequencing is the sequencing of protein-coding 
regions of DNA, which constitute 1.5-2% of the entire 
genome. In 2012, the Norwegian Biotechnology Advi-
sory Board (36) filed a complaint against the ABC 
Study, arguing that exome sequencing may generate 
incidental findings that could potentially have a large 
impact on participant’s lives and that participants were 
not aware of this risk when they donated their blood 
samples. A year later, in 2013, a medical geneticist at 
the Haukeland University Hospital in Bergen published 
a book in which the ABC Study was prominently fea-
tured and heavily criticized on these grounds (37). Due 
to these controversies, the exome sequencing project 
went through an additional review by the National 
Committee of Medical and Health Research Ethics, 
which resulted in a confirmation of the ethics approval 
for the project. A number of other MoBa-based exome 
sequencing projects have now been initiated and app-
roved. The MoBa consent is considered to be a legally 
and ethically valid foundation for these projects. 
 
 
RESULTS OF ABC CASE-FINDING PROCEDURES 
 
Current status  
The number of ASD cases identified, by source of 
identification, is shown in Table 5. By the end of 2012, 
there were 518 ASD cases in MoBa, of whom 195 
(38%) had been diagnosed through the clinical assess-
ments while the remaining 323 (62%) had ASD diag-
noses assigned by regular health services (12 of these 
children were assessed by the ABC study at age three 
years and did not meet the diagnostic criteria for ASD 
at that time). Of the 518 ASD cases, there were 208 
with autistic disorder, 122 with Asperger’s disorder, 
and 188 with PDD-NOS. The male-to-female ratio for 
ASDs is 4.7 (95% confidence interval, 4.3-5.2). For 
MoBa participants born in 2003 and earlier (aged 9 
years and older at the end of follow-up), the overall 
ASD prevalence is now 0.7-0.8%, which is in line with 
the nationwide prevalence estimates for Norway (38). 
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Table 5.  ABC Study: Sources of Identified ASD Cases. 
 
 Total Invited Assessed ASD 
Source n n % of total n % participation n PPV (ASD) 
36-month screening a   873 873 100 450   52 62 14 
5- and 7-year Q b     81   81 100   40   49 19 48 
Referrals     83   83 100   78   94 46 58 
NPR 2008 – 2011   215 215 100   61   28 58 95 
Controls 1811 920   51 368   40   3 0.8 
Twins d     53   53 100   24   47   0   0 
Siblings e     11   11 100   11 100   7 64 
Subtotal  3127 2236   72 1032   46 195 19 
NPR non-validated ASD   323      0    0      0     0 323 --- 
Total 3450 2236   65 1032   46 518 --- 
Updated per December 31, 2012. 
ABC = Autism Birth Cohort. ASD = Autism spectrum disorder. PPV = Positive predictive value.  
a This refers to the original and revised screening algorithms combined. PPV(ASD) for the original algorithm was 11%, whereas the 
PPV(ASD) for the revised algorithm is 17%.  
b This refers to the children who were detected and invited on the basis of the 5- and 7- year questionnaires. A lot more reported 
ASDs in these questionnaires but were already detected via other routes. 
d If any of the invited children (including the controls) had a twin, the twin was also invited.  
e Siblings were assessed if there was reason to suspect ASD. 
 
 
If these figures hold for the entire cohort, we expect to 
identify 800-900 ASD cases by the time the whole 
MoBa population has reached ten years of age in 2019. 
 
Screening results  
The questionnaire-based screening for ASDs did not 
turn out as planned, for several reasons. First, the 
questionnaire response rates were lower than expected: 
59% for the 36-month questionnaire, 53% for the 5-
year questionnaire, and 54% for the 7-year question-
naire. Second, a lot of invited screen-positives chose 
not to participate in the clinical assessment, as shown 
in Table 5; the proportions accepting invitations were 
52% for 36-month screen-positives and 49% for child-
ren identified from to the 5- and 7-year questionnaires. 
Third, it soon became apparent that both the sensitivity 
and the specificity of the 36-month screening algo-
rithm (Table 1) were too low. To limit the number of 
false positives, an additional step was added to the 36-
month screening algorithm for children born in 2004 
and later: a question about whether others had ex-
pressed worry for the child’s development. After the 
revision, children were only defined as screen-positive 
if meeting one of the five initial criteria AND having a 
positive response to the worry question (Table 1). This 
revision improved specificity considerably, but came 
at the cost of reducing sensitivity. The current sensiti-
vity estimate for the revised algorithm is 36%, and the 
specificity estimate is 99%. The positive predictive 
value for ASD was 11% with the initial algorithm, but 
increased to 17% with the revised algorithm. 
 It also became clear that some children cannot be 
reliably diagnosed with ASD at an early age even if 
they do have the disorder. There were a number of 
children who were screen-positive and clearly had 
signs of ASDs at age three but for whom there was not 
enough evidence to justify a diagnosis at that age. 
Some of those children have later been diagnosed with 
ASDs by the ordinary healthcare system (12 children 
at present). 
 
Registry linkages  
Questionnaire-based screening was originally intended 
to be the major source of ASD cases in the ABC 
Study, but as shown in Table 5, the overwhelming 
majority has been identified through the NPR. Our 
experiences from the NPR linkages show that the 
technical aspects of data collection from healthcare 
institutions work well and that the validity of the 
diagnoses appears to be high for ASDs overall. Of the 
61 ASD cases who participated in the clinical assess-
ment after having been detected through the NPR, 58 
were found to meet the DSM-IV criteria for ASDs, 
generating a positive predictive value (PPV) of 95% 
[95% CI, 86-99%]. This PPV estimate should be inter-
preted with caution, however, given the low partici-
pation rate among those who were invited. Future re-
cord-based validation of the remaining NPR diagnoses 
is required to determine the validity more precisely. 
 
 
ABC-BASED RESEARCH GRANTS AND 
PUBLISHED RESULTS 
 
ASD case identification and ascertainment  
The initial methods paper describing the ABC Study 
was published in 2010 (39). The first analysis of ASD 
prevalence in Norwegian children, based on the first 
three years of data from the NPR, came out in 2012 
(38). This article also included prevalence estimates 
for ADHD, epilepsy, and cerebral palsy. In 2013, we 
published a study of whether analyses of ASD risk 
factors in MoBa and the ABC Study are likely to be 
affected by selection bias (40). We investigated six 
selected exposure-disease associations for which we 
were able to replicate the analyses in a registry-based 
data set including the entire Norwegian child popula-
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tion. This study was modelled on the previous article 
about selection bias in MoBa (41), and the conclusion 
was similar: there were no substantial differences 
between MoBa and Norway as a whole, indicating that 
analyses of risk factors in the ABC Study will not be 
affected by selection bias (40). 
 The first article about early ASD screening was 
published in 2014 (42). This publication investigated 
the ability of the Modified Checklist for Autism in 
Toddlers (M-CHAT) (43) to predict the development 
of ASDs in children. The M-CHAT is an established 
23-item screening instrument for ASDs designed for 
use in children aged 16-30 months (43). The M-CHAT 
items were embedded in the MoBa 18-month question-
naire. Two different cut-off levels have been proposed 
for the M-CHAT (43), and our analyses showed that 
neither of them performed well, with a sensitivity of 
20.8% and 34.1%, respectively (42). In other words, 
the M-CHAT failed to identify the majority of children 
with ASDs at 18 months of age. Specificity was also 
low, with large numbers of normally developed child-
ren scoring above cut-off levels (42). Our conclusion 
was that ASD screening at 18 months of age does not 
appear to work well (42).  
Maternal nutrition in pregnancy  
An insufficient supply of micronutrients during preg-
nancy is hypothesized to put the fetus at increased risk 
of neurodevelopmental disorders later in life. Women 
exposed to famine during early pregnancy have an 
increased risk of having children with schizophrenia, 
and this is thought to result from a lack of essential 
micronutrients (44,45). In the early 1990s, it was de-
monstrated that maternal supplementation of folic acid 
(vitamin B9) in early pregnancy prevents against 
neural tube defects in children (46), which led to the 
recommendation that all women planning to get preg-
nant should start taking folic acid at least one month 
before conception (47). A case-control study from 
California recently found that women who took folic 
acid supplements in pregnancy had a decreased risk of 
having children with ASDs (48). 
 In our analyses based on MoBa and the ABC Study, 
we found that maternal use of folic acid during the 
time interval from 4 weeks before to 8 weeks after the 
start of pregnancy reduced the child’s risk of severe 
language delay at age three years by 45% (49). Severe 
language delay is one of the core symptoms of ASDs, 
and it is also a feature of most other severe neurodeve-
lopmental disturbances in children. Laboratory analyses 
showed good agreement between maternal self-report 
of supplement use and the levels of folate measured in 
their plasma samples (50). The article about language 
delay was followed by another one about ASDs speci-
fically, in which we found a similar reduction in risk 
for autistic disorder among children whose mothers 
used folic acid (51). The adjusted odds ratio of autistic 
disorder was 0.61 (95% confidence interval, 0.41-0.90) 
in children of folic acid users compared to children of 
non-users (51). The reduction in risk was limited to 
those who had used folic acid in early pregnancy; no 
reduction was observed for those who started after 
week 8 of pregnancy (51). There was no reduction in 
ASD risk associated with other dietary supplements 
(51). Our findings do not establish a causal relation 
between folic acid and ASD risk, but they do support 
current recommendations of folic acid supplementa-
tion. If this were to represent a causal biological 
mechanism, folic acid would be the first preventive 
measure identified against ASDs. 
 In analyses of nationwide health registry data, we 
showed that a short interval between pregnancies is 
associated with an increase in risk of autistic disorder 
in the later-born child (52). This has also been shown 
previously (53), and the association is hypothesized to 
result from a depletion of micronutrients in mothers 
with closely spaced pregnancies (52,53). Consequent-
ly, the finding provides further support for the 
hypothesis that folate and folic acid affect children’s 
risk of ASDs. 
 
Parental overweight and obesity  
Maternal obesity is another known risk factor for 
neurodevelopmental disorders in children. A previous 
study from California found an increase in risk of 
ASDs in children whose mothers were obese (body 
mass index ≥30) before the start of pregnancy (54). 
Our analyses in MoBa and the ABC Study confirmed 
these findings for autistic disorder and Asperger’s 
disorder (55). However, the associations with maternal 
obesity were substantially weakened by adjustment for 
paternal body mass index, and paternal obesity turned 
out to be a stronger and more robust risk factor than 
maternal obesity (55). There appears to be a dose-
response relation, with an exponential increase in ASD 
risk by increasing paternal BMI (55). We do not know 
why overweight and obesity in the father might in-
crease the risk of ASD in the child, but potential 
explanations may be through genetic associations or 
through epigenetic alterations induced by paternal 
obesity (55). However, our analyses need to be repli-
cated in other study samples before paternal obesity 
may be declared as a risk factor for ASDs, and the risk 
associated with paternal obesity should be studied for 
other neurodevelopmental disorders as well. 
 
Early child growth  
The first article published under this aim was a study 
of early growth trajectories in ASDs (56). Previous 
studies, mainly from clinic-based study samples, have 
shown an increase in head growth in the first year of 
life in children with ASDs, and increased head size has 
been proposed to be an early biomarker of ASD (57). 
Our analyses based on MoBa and the ABC Study did 
not replicate these findings: boys with ASDs had si-
milar mean head circumference to other boys, although 
there was a trend towards an increase in macrocephaly 
at 12 months of age. Girls with ASDs actually had a 
smaller head size on average. We believe the discre-
pancy between our findings and those of previous 
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studies can be explained by differences in recruitment 
and case ascertainment – population-based recruitment 
is likely to bring in a wider range of ASD cases that 
are more representative of the autism spectrum as a 
whole. Our findings do not negate those of previous 
studies, but they do indicate that increased head growth 
is not a generally applicable biomarker for ASDs in 
children. 
 
FUTURE PLANS FOR THE ABC STUDY 
 
Analyses of plasma and RNA samples  
In the years to come, the majority of research funds 
will be allocated to analyses of biological materials, 
which is where the ABC Study really is poised to 
make novel contributions. No other cohort has an array 
of biological samples comparable to that of MoBa. 
MoBa is unique in including full family trios, and the 
cohort is the only one in which analyses of DNA, 
RNA and plasma can be integrated. All the biological 
samples were collected during the fetal period or right 
after the child’s birth, which is when the pathogenesis 
of ASDs is most likely to be occurring. 
 Analyses of plasma and RNA samples will be con-
ducted by the Center for Infection and Immunity at the 
Mailman School of Public Health, Columbia Univer-
sity. These analyses will be performed on plasma 
samples from mothers, fathers and children, and RNA 
samples from children’s cord blood. The results will 
be combined with genetic data to investigate gene-
environment interactions. The following will be 
investigated: 
 
• Prenatal and perinatal microbial exposures 
• Maternal and child innate immune and inflamma-
tory responses 
• Maternal and child biomarkers of autism risk 
(proteomics and metabolomics) 
• Prenatal and postnatal exposure to xenobiotics 
(heavy metals, organic compounds) 
 
Genetic analyses  
Exome sequencing has been performed on 200 family 
trios (children, mothers and fathers) of ASD cases 
identified through the ABC Study. The sequencing has 
been performed at the Wellcome Trust Sanger Institute 
in Cambridge in the United Kingdom, and the data are 
now undergoing analysis. The goal is to eventually 
conduct exome sequencing on all the ASD children 
and their parents and to combine the exome data with 
similar data for other neurodevelopmental disorders. 
 
Analyses of deciduous teeth  
These analyses will utilize deciduous teeth collected 
by the MoBa tooth biobank. A laboratory has not been 
chosen for the analyses, but the intention is to inves-
tigate whether ASD risk is associated with pre- and 
postnatal exposure to heavy metals, acetaminophen, 
ibuprofen and/or semi-volatile organic compounds. 
Other ongoing analyses  
Results of the 36-month screening for ASDs will be 
published when the medical record reviews have been 
completed for ASD cases detected through the NPR. 
Other ongoing studies are investigating comorbid psy-
chiatric and gastrointestinal disorders in children with 
ASDs and patterns of medication use in these children. 
It is well known that psychiatric and gastrointestinal 
comorbidity is common among children with ASDs, 
but there is little data available from population-based 
study samples. 
 
International collaboration  
As a result of our work in the ABC Study, the ABC 
Study collaborators were invited to participate in the 
International Collaboration for Autism Registry Epide-
miology (iCARE) from 2009 2013 (58). This collabo-
ration was funded by the American research founda-
tion Autism Speaks and included health registries from 
six countries: Denmark, Sweden, Finland, Norway, 
Israel and Western Australia. In 2013, iCARE was 
succeeded by the Multigenerational Familial and 
Environmental Risk for Autism (MINERvA) Network, 
which is funded by the Eunice Kennedy Shriver 
National Institute of Child Health and Development 
and includes the six iCARE countries plus the state-
wide California autism registry. Until now Norway has 
only contributed nationwide health registry data to 
these collaborations, but we do aim to also use MoBa 
and ABC data in international collaborations in the 
future. It would be particularly useful to combine 
MoBa/ABC data with data from comparable child 
cohorts such as the Danish National Birth Cohort (59). 
 
Collaboration with other studies of neuro-
developmental disorders in MoBa  
Since the initiation of the ABC Study, several other 
studies of neurodevelopmental disorders have been es-
tablished in MoBa. The ABC Study investigators will 
contribute to coordinate analyses of risk factors and 
developmental trajectories across disorders, particular-
ly with regards to analyses of biological samples. 
 
Future data collection  
The current data collection grant from the NINDS 
expires in 2015. In the years to come, the priority will 
be the analyses of data and biological samples that 
have already been collected, but we will continue the 
identification and follow-up of ASD cases through 
annual linkages with the NPR. All new ASD cases will 
subsequently be confirmed and characterized through 
medical record reviews. 
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